Cargando…

Pharmacodynamics of natalizumab extended interval dosing in MS

OBJECTIVE: To determine if the concentration and saturation of natalizumab (NTZ) administration at extended interval dosing (EID; every 5–8 weeks) over 18 months is able to be maintained in the range considered adequate to sustain the clinical efficacy of NTZ. METHODS: In a cross-sectional assessmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhovtis Ryerson, Lana, Li, Xiaochun, Goldberg, Judith D., Hoyt, Tamara, Christensen, Angel, Metzger, Ryan R., Kister, Ilya, Foley, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057061/ https://www.ncbi.nlm.nih.gov/pubmed/32019876 http://dx.doi.org/10.1212/NXI.0000000000000672

Ejemplares similares

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

Incomplete Susac syndrome exacerbated after natalizumab
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2015)

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
por: Smith, Tyler E, et al.
Publicado: (2022)

Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
por: Foley, John F., et al.
Publicado: (2020)

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
por: Pelle, Juliette, et al.
Publicado: (2023)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center
por: Parrotta, Erica, et al.
Publicado: (2020)

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study
por: Riancho, Javier, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
por: Santiago-Setien, Pilar, et al.
Publicado: (2023)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic
por: Bringeland, Gerd Haga, et al.
Publicado: (2021)

Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic
por: Magro, Giuseppe, et al.
Publicado: (2022)

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
por: Chang, Ih, et al.
Publicado: (2020)

COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
por: Borriello, Giovanna, et al.
Publicado: (2020)

End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab
por: Magro, Giuseppe, et al.
Publicado: (2021)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

CD4 cell response to interval therapy with natalizumab
por: Berkovich, Regina, et al.
Publicado: (2015)

Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
por: Bringeland, Gerd Haga, et al.
Publicado: (2020)

Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing
por: Rempe, Torge, et al.
Publicado: (2020)

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
por: Perncezky, Julian, et al.
Publicado: (2022)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
por: Maarouf, Adil, et al.
Publicado: (2020)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
por: Major, Eugene O., et al.
Publicado: (2016)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Natalizumab treatment reduces microglial activation in the white matter of the MS brain
por: Sucksdorff, Marcus, et al.
Publicado: (2019)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_59ln2j4g524d53vhrq1ao85025